Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Artery Infusion of Oxaliplatin, Leucovorin, and 2400 mg/m² Fluorouracil Versus Hepatic Artery Infusion of Oxaliplatin, Leucovorin, and 1200 mg/m² Fluorouracil for Unresectable Hepatocellular Carcinoma: a Randomised Phase 3 Non-inferiority Trial

NCT04667351 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04667351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04667351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Artery Infusion of Oxaliplatin, Leucovorin, and 2400 mg/m² Fluorouracil Versus Hepatic Artery Infusion of Oxaliplatin, Leucovorin, and 1200 mg/m² Fluorouracil for Unresectable Hepatocellular Carcinoma: a Randomised Phase 3 Non-inferiority Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2019
Completion date
December 1, 2022
Enrollment
400 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma